Roche Halts Trials of Diabetes Drug on Safety Concern
This article is for subscribers only.
Roche Holding AG halted testing of its most-advanced experimental diabetes drug over safety concerns and said it’s reassessing its research and development program for heart and metabolic diseases.
The Data and Safety Monitoring Board, an independent body, recommended halting the trial of the treatment, aleglitazar, on patients with recent heart trouble and type-2 diabetes because of concerns about the drug’s safety and effectiveness, the Basel, Switzerland-based drugmaker said in a statement today. Heart failure, kidney impairment and bone fractures were side effects in the study, spokesman Alexander Klauser said.